The global Neoantigen Vaccine market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The publisher report includes an overview of the development of the Neoantigen Vaccine industry chain, the market status of Lung Cancer (Personalized Vaccine, Off-the shelf Vaccine), Melanoma Cancer (Personalized Vaccine, Off-the shelf Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neoantigen Vaccine.
Regionally, the report analyzes the Neoantigen Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neoantigen Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Neoantigen Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neoantigen Vaccine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Personalized Vaccine, Off-the shelf Vaccine).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neoantigen Vaccine market.
Regional Analysis: The report involves examining the Neoantigen Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neoantigen Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Neoantigen Vaccine:
Company Analysis: Report covers individual Neoantigen Vaccine players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neoantigen Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Cancer, Melanoma Cancer).
Technology Analysis: Report covers specific technologies relevant to Neoantigen Vaccine. It assesses the current state, advancements, and potential future developments in Neoantigen Vaccine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neoantigen Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Neoantigen Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Personalized Vaccine
Off-the shelf Vaccine
Market segment by Application
Lung Cancer
Melanoma Cancer
Gastrointestinal Cancer
Brain Cancer
Others
Market segment by players, this report covers
Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Neoantigen Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neoantigen Vaccine, with revenue, gross margin and global market share of Neoantigen Vaccine from 2019 to 2024.
Chapter 3, the Neoantigen Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Neoantigen Vaccine market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neoantigen Vaccine.
Chapter 13, to describe Neoantigen Vaccine research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Market Overview
1.1 Product Overview and Scope of Neoantigen Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neoantigen Vaccine by Type
1.3.1 Overview: Global Neoantigen Vaccine Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Neoantigen Vaccine Consumption Value Market Share by Type in 2023
1.3.3 Personalized Vaccine
1.3.4 Off-the shelf Vaccine
1.4 Global Neoantigen Vaccine Market by Application
1.4.1 Overview: Global Neoantigen Vaccine Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Lung Cancer
1.4.3 Melanoma Cancer
1.4.4 Gastrointestinal Cancer
1.4.5 Brain Cancer
1.4.6 Others
1.5 Global Neoantigen Vaccine Market Size & Forecast
1.6 Global Neoantigen Vaccine Market Size and Forecast by Region
1.6.1 Global Neoantigen Vaccine Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Neoantigen Vaccine Market Size by Region, (2019-2030)
1.6.3 North America Neoantigen Vaccine Market Size and Prospect (2019-2030)
1.6.4 Europe Neoantigen Vaccine Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Neoantigen Vaccine Market Size and Prospect (2019-2030)
1.6.6 South America Neoantigen Vaccine Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Neoantigen Vaccine Market Size and Prospect (2019-2030)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Neoantigen Vaccine Product and Solutions
2.1.4 Pfizer Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Merck & Co Inc
2.2.1 Merck & Co Inc Details
2.2.2 Merck & Co Inc Major Business
2.2.3 Merck & Co Inc Neoantigen Vaccine Product and Solutions
2.2.4 Merck & Co Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Merck & Co Inc Recent Developments and Future Plans
2.3 Eli Lilly and Company
2.3.1 Eli Lilly and Company Details
2.3.2 Eli Lilly and Company Major Business
2.3.3 Eli Lilly and Company Neoantigen Vaccine Product and Solutions
2.3.4 Eli Lilly and Company Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Eli Lilly and Company Recent Developments and Future Plans
2.4 BioNTech
2.4.1 BioNTech Details
2.4.2 BioNTech Major Business
2.4.3 BioNTech Neoantigen Vaccine Product and Solutions
2.4.4 BioNTech Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 BioNTech Recent Developments and Future Plans
2.5 Roche Holding AG
2.5.1 Roche Holding AG Details
2.5.2 Roche Holding AG Major Business
2.5.3 Roche Holding AG Neoantigen Vaccine Product and Solutions
2.5.4 Roche Holding AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Roche Holding AG Recent Developments and Future Plans
2.6 OSE Immunotherapeutics
2.6.1 OSE Immunotherapeutics Details
2.6.2 OSE Immunotherapeutics Major Business
2.6.3 OSE Immunotherapeutics Neoantigen Vaccine Product and Solutions
2.6.4 OSE Immunotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 OSE Immunotherapeutics Recent Developments and Future Plans
2.7 Gritstone Bio
2.7.1 Gritstone Bio Details
2.7.2 Gritstone Bio Major Business
2.7.3 Gritstone Bio Neoantigen Vaccine Product and Solutions
2.7.4 Gritstone Bio Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Gritstone Bio Recent Developments and Future Plans
2.8 Moderna
2.8.1 Moderna Details
2.8.2 Moderna Major Business
2.8.3 Moderna Neoantigen Vaccine Product and Solutions
2.8.4 Moderna Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Moderna Recent Developments and Future Plans
2.9 Avidea Technologies
2.9.1 Avidea Technologies Details
2.9.2 Avidea Technologies Major Business
2.9.3 Avidea Technologies Neoantigen Vaccine Product and Solutions
2.9.4 Avidea Technologies Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Avidea Technologies Recent Developments and Future Plans
2.10 Vaccibody AS
2.10.1 Vaccibody AS Details
2.10.2 Vaccibody AS Major Business
2.10.3 Vaccibody AS Neoantigen Vaccine Product and Solutions
2.10.4 Vaccibody AS Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Vaccibody AS Recent Developments and Future Plans
2.11 Agenus Inc
2.11.1 Agenus Inc Details
2.11.2 Agenus Inc Major Business
2.11.3 Agenus Inc Neoantigen Vaccine Product and Solutions
2.11.4 Agenus Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Agenus Inc Recent Developments and Future Plans
2.12 Novogene
2.12.1 Novogene Details
2.12.2 Novogene Major Business
2.12.3 Novogene Neoantigen Vaccine Product and Solutions
2.12.4 Novogene Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Novogene Recent Developments and Future Plans
2.13 ZIOPHARM Oncology
2.13.1 ZIOPHARM Oncology Details
2.13.2 ZIOPHARM Oncology Major Business
2.13.3 ZIOPHARM Oncology Neoantigen Vaccine Product and Solutions
2.13.4 ZIOPHARM Oncology Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 ZIOPHARM Oncology Recent Developments and Future Plans
2.14 ISA Pharmaceuticals
2.14.1 ISA Pharmaceuticals Details
2.14.2 ISA Pharmaceuticals Major Business
2.14.3 ISA Pharmaceuticals Neoantigen Vaccine Product and Solutions
2.14.4 ISA Pharmaceuticals Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 ISA Pharmaceuticals Recent Developments and Future Plans
2.15 BrightPath Biotherapeutics
2.15.1 BrightPath Biotherapeutics Details
2.15.2 BrightPath Biotherapeutics Major Business
2.15.3 BrightPath Biotherapeutics Neoantigen Vaccine Product and Solutions
2.15.4 BrightPath Biotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 BrightPath Biotherapeutics Recent Developments and Future Plans
2.16 Vaximm AG
2.16.1 Vaximm AG Details
2.16.2 Vaximm AG Major Business
2.16.3 Vaximm AG Neoantigen Vaccine Product and Solutions
2.16.4 Vaximm AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.16.5 Vaximm AG Recent Developments and Future Plans
2.17 Medigene AG
2.17.1 Medigene AG Details
2.17.2 Medigene AG Major Business
2.17.3 Medigene AG Neoantigen Vaccine Product and Solutions
2.17.4 Medigene AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.17.5 Medigene AG Recent Developments and Future Plans
2.18 Genocea Biosciences Inc
2.18.1 Genocea Biosciences Inc Details
2.18.2 Genocea Biosciences Inc Major Business
2.18.3 Genocea Biosciences Inc Neoantigen Vaccine Product and Solutions
2.18.4 Genocea Biosciences Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.18.5 Genocea Biosciences Inc Recent Developments and Future Plans
2.19 Advaxis
2.19.1 Advaxis Details
2.19.2 Advaxis Major Business
2.19.3 Advaxis Neoantigen Vaccine Product and Solutions
2.19.4 Advaxis Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.19.5 Advaxis Recent Developments and Future Plans
2.20 Nouscom
2.20.1 Nouscom Details
2.20.2 Nouscom Major Business
2.20.3 Nouscom Neoantigen Vaccine Product and Solutions
2.20.4 Nouscom Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2024)
2.20.5 Nouscom Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Neoantigen Vaccine Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Neoantigen Vaccine by Company Revenue
3.2.2 Top 3 Neoantigen Vaccine Players Market Share in 2023
3.2.3 Top 6 Neoantigen Vaccine Players Market Share in 2023
3.3 Neoantigen Vaccine Market: Overall Company Footprint Analysis
3.3.1 Neoantigen Vaccine Market: Region Footprint
3.3.2 Neoantigen Vaccine Market: Company Product Type Footprint
3.3.3 Neoantigen Vaccine Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Neoantigen Vaccine Consumption Value and Market Share by Type (2019-2024)
4.2 Global Neoantigen Vaccine Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
5.1 Global Neoantigen Vaccine Consumption Value Market Share by Application (2019-2024)
5.2 Global Neoantigen Vaccine Market Forecast by Application (2025-2030)
6 North America
6.1 North America Neoantigen Vaccine Consumption Value by Type (2019-2030)
6.2 North America Neoantigen Vaccine Consumption Value by Application (2019-2030)
6.3 North America Neoantigen Vaccine Market Size by Country
6.3.1 North America Neoantigen Vaccine Consumption Value by Country (2019-2030)
6.3.2 United States Neoantigen Vaccine Market Size and Forecast (2019-2030)
6.3.3 Canada Neoantigen Vaccine Market Size and Forecast (2019-2030)
6.3.4 Mexico Neoantigen Vaccine Market Size and Forecast (2019-2030)
7 Europe
7.1 Europe Neoantigen Vaccine Consumption Value by Type (2019-2030)
7.2 Europe Neoantigen Vaccine Consumption Value by Application (2019-2030)
7.3 Europe Neoantigen Vaccine Market Size by Country
7.3.1 Europe Neoantigen Vaccine Consumption Value by Country (2019-2030)
7.3.2 Germany Neoantigen Vaccine Market Size and Forecast (2019-2030)
7.3.3 France Neoantigen Vaccine Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Neoantigen Vaccine Market Size and Forecast (2019-2030)
7.3.5 Russia Neoantigen Vaccine Market Size and Forecast (2019-2030)
7.3.6 Italy Neoantigen Vaccine Market Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Vaccine Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Neoantigen Vaccine Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Neoantigen Vaccine Market Size by Region
8.3.1 Asia-Pacific Neoantigen Vaccine Consumption Value by Region (2019-2030)
8.3.2 China Neoantigen Vaccine Market Size and Forecast (2019-2030)
8.3.3 Japan Neoantigen Vaccine Market Size and Forecast (2019-2030)
8.3.4 South Korea Neoantigen Vaccine Market Size and Forecast (2019-2030)
8.3.5 India Neoantigen Vaccine Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Neoantigen Vaccine Market Size and Forecast (2019-2030)
8.3.7 Australia Neoantigen Vaccine Market Size and Forecast (2019-2030)
9 South America
9.1 South America Neoantigen Vaccine Consumption Value by Type (2019-2030)
9.2 South America Neoantigen Vaccine Consumption Value by Application (2019-2030)
9.3 South America Neoantigen Vaccine Market Size by Country
9.3.1 South America Neoantigen Vaccine Consumption Value by Country (2019-2030)
9.3.2 Brazil Neoantigen Vaccine Market Size and Forecast (2019-2030)
9.3.3 Argentina Neoantigen Vaccine Market Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Vaccine Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Neoantigen Vaccine Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Neoantigen Vaccine Market Size by Country
10.3.1 Middle East & Africa Neoantigen Vaccine Consumption Value by Country (2019-2030)
10.3.2 Turkey Neoantigen Vaccine Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Neoantigen Vaccine Market Size and Forecast (2019-2030)
10.3.4 UAE Neoantigen Vaccine Market Size and Forecast (2019-2030)
11 Market Dynamics
11.1 Neoantigen Vaccine Market Drivers
11.2 Neoantigen Vaccine Market Restraints
11.3 Neoantigen Vaccine Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Neoantigen Vaccine Industry Chain
12.2 Neoantigen Vaccine Upstream Analysis
12.3 Neoantigen Vaccine Midstream Analysis
12.4 Neoantigen Vaccine Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom
听
听
*If Applicable.
